Viewpoints of Practicing Rheumatologists: Case Discussions in RA

Slides:

Advertisements

Similar presentations

Disease Modifying Anti-Rheumatic Drugs (DMARDs) Immunomodulatory and immunosuppresive Xenobiotic – Gold salts – Azathioprine – Methotrexate Biological.

Advertisements

Treatment Management of Rheumatoid Arthritis. Findings and In Depth Analysis.

What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis.

Planning for Biosimilars: Infliximab Professor Ray Fitzpatrick Secondary Care lead Keele University Clinical Director of Pharmacy Royal Wolverhampton NHS.

Save The Date! Fatigue and Arthritis Wednesday 13 th April 2016 Holiday Inn-Southampton Free Health Care Professional Delegate Places Book Early Signed_________________.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update Smolen.

BIOLOGIC DOSE REDUCTION IN RHEUMATOID ARTHRITIS: WHAT DO PATIENTS THINK? RESULTS FROM A PATIENT AND PUBLIC INVOLVEMENT EVENT Dinny Wallis1, Christopher.

ARTHRITIS & RHEUMATOLOGY

Recommendations for the treatment of established RA (disease duration 6 month or longer). Biologic, biological originator DMARD or boDMARD; DMARD, disease-modifying.

Objective Assessment of RA: Expanding the Horizons

Clinical Developments in Inflammatory Arthritis 2017

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Goals of Therapy for Patients With UC

Optimizing Use of Biological Agents in Ulcerative Colitis

Introduction/Background

Introducing JAK Inhibitors in Rheumatoid Arthritis

Diagnosing Rheumatoid Arthritis Early

Thrombosis, Cancer, and NOACs

REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Study Design

Posters & Abstracts from Amsterdam

Biosimilars in RA: A Blessing or a Curse?

Novel Small Molecule Therapies in Rheumatoid Arthritis

Complicated Cases in Ulcerative Colitis

Innovative Insulin Combinations: A New strategy for the Person With T2DM.

Managing RA: Telepartnership Between PCP and Rheumatologist

Minding the Gap Rheumatoid Arthritis Advances From London 2016

Decision-making in the eRA of Treating to Target

What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data

Clinical Updates in RA: New Developments and Insights From Washington

Team-Based Perspectives on Successful Approaches in Treating Obesity

Is RA Treatment Addressing the Real Needs of Patients?

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

BeSt Study: Patient Characteristics Total Population Female 67% Male % Age (years) Duration of symptoms (weeks) 23 Time diagnosis.

Understanding Comparative Effectiveness Data in Psoriatic Arthritis

Biotherapeutics.

Debating the Issues in Rheumatoid Arthritis with the Experts: Early Treatment and Targets.

Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Advancing the Treatment of IBD With Biologics

Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma

Advances in Rheumatoid Arthritis Management

Early Referral for Patients With IBD Failing Conventional Therapies

What's New in Therapeutic Options for Moderate to Severe RA?

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Current Challenges in Managing Hemophilia

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Application of Biologics in IBD:

Communicating With Your Patients About Major Depressive Disorder

Updates in RA, PsA, and Biosimilars

Treating Atypical Hemolytic Uremic Syndrome A Case Discussion

Selecting Treatment Approaches in Hemophilia

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Nat. Rev. Rheumatol. doi: /nrrheum

Low-dose glucocorticoid chronotherapy in rheumatoid arthritis (RA) include the night-time-release prednisone, a timing drug release formulation with administration.

Clinical response in patients with early and established RA at month 24. *p

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Rheumatoid Arthritis.

Early Diagnosis and Management of SSc-ILD

Enthesitis in Psoriatic Arthritis: Disease, Diagnosis and Decisions

Patient disposition after 2 years of treatment.

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

Treatment Advances for RA

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.

Presentation transcript:

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

Adverse Effects of Synthetic DMARDs

Summary of Benefits: Biologic DMARDs

Summary of Benefits

Methotrexate: Maximize and Maintain

Tofacitinib vs MTX

Case 2: A Simple Case of Rheumatoid Arthritis?

Tight Control Strategy in Rheumatoid Arthritis

Individualizing Treatment

Patient-Reported Outcomes

What Comes After Remission?

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)